Amanda J. Stolarz profile photo

Amanda J. Stolarz

Federal Grant PI

Assistant Professor

University of Arkansas for Medical Sciences

faculty

Pharmaceutical Science, College of Pharmacy

astolarz@uams.edu

10 h-index 27 pubs 267 cited

Research Areas

Lymphatic Dysfunction and Lymphedema Research Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors Immune Cell Function and Interaction Drug Transport and Resistance Mechanisms Health and Medical Research Impacts

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Amanda J. Stolarz investigates mechanisms of lymphatic dysfunction and potential therapeutic interventions, particularly in the context of chemotherapy-induced toxicity. Her federally funded research, supported by a $368,387 grant from the NIH/National Cancer Institute, focuses on exploring the role of Ryanodine Receptors as therapeutic targets to prevent doxorubicin-induced lymphatic dysfunction. This work is informed by her publications examining drug-related lymphedema, including studies on dantrolene's preventative effects and the clinical relevance of animal models for lymphatic disorders.

Dr. Stolarz's research also extends to the function of endothelial cells and their relationship with macrophages, exploring their role as gatekeepers in vascular health. She has published on how PCSK9 influences efferocytosis in endothelial cells and contributes to vascular aging. Her group's work includes developing methodologies for real-time evaluation of calcium dynamics and contractility in isolated lymphatic vessels. She has a h-index of 10 with 27 total publications and 267 citations, and collaborates with researchers including Soumiya Pal and Nancy Rusch at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 10
  • Publications: 27
  • Citations: 267

Selected Publications

  • Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema (2025) DOI
  • Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats (2024) DOI
  • Proteomics Approach to Identify Anthracycline-induced Cardiotoxicity Mechanisms in Human Cardiac Fibroblasts (2024) DOI
  • JoVE Video Dataset (2024) DOI
  • Real-Time Evaluation of Absolute, Cytosolic, Free Ca<sup>2+</sup> and Corresponding Contractility in Isolated, Pressurized Lymph Vessels (2024) DOI
  • PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging (2023) DOI
  • Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022) DOI
  • Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy (2022) DOI
  • Opinion: Endothelial Cells - Macrophage-Like Gatekeepers? (2022) DOI
  • Hypertension Induces Contractile Dysfunction in Rat Mesenteric Lymph Vessels (2022) DOI
  • Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies (2022) DOI
  • Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation (2021) DOI
  • Mechanisms of Increased Infarct Volume in a Rat Model of Ischemic Stroke: Implications for Leptomeningeal Collateral Artery Function and Beta Blocker Therapy (2021) DOI

Federal Grants 1 $368,387 total

NIH/National Cancer Institute Contact PI Aug 2023 - Jul 2028

Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction

National Cancer Institute $368,387 R37

Grants & Funding

  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
  • Doxorubicin suppression of lymphatic function and therapeutic reversal NIH Co-Investigator
  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator
  • Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
  • Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction NIH/Nat. Cancer Institute Principal Investigator

Collaborators

Researchers in the database who share publications

Soumiya Pal University of Arkansas for Medical Sciences 7 shared publications Nancy Rusch University of Arkansas for Medical Sciences 6 shared publications Ashim K. Bagchi University of Arkansas for Medical Sciences 4 shared publications Shengyu Mu University of Arkansas for Medical Sciences 4 shared publications Sung W. Rhee University of Arkansas for Medical Sciences 3 shared publications David S. Henry University of Arkansas for Medical Sciences 3 shared publications Bijay P. Chhetri University of Arkansas at Little Rock 2 shared publications Robert J. Griffin University of Arkansas for Medical Sciences 2 shared publications

Similar Researchers

Based on overlapping research topics

J.C. Hsu University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics
Brittney R. Garner University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics
K. C. Stine University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics
James C. Fuscoe National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics
Carrie L. Moland National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics
Samaneh Goorani University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies Cancer Treatment and Pharmacology Cardiovascular Function and Risk Factors
Good match 4 shared topics